Cervical Dysplasia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Cervical cancer ranks as the second most prevalent cancer in young women. It stands among the leading causes of cancer-related deaths in women, particularly in minorities and impoverished countries. The main precursor to cervical cancer is cervical dysplasia, a premalignant condition triggered primarily by an oncogenic strain of the human papillomavirus (HPV), a sexually transmitted infection. However, not all women infected with the virus develop cervical dysplasia or cancer, suggesting multiple host factors contribute to disease progression. Fortunately, many of these factors, such as nutrient deficiencies, can be reversed, leading to regression of dysplastic lesions. Cervical dysplasia arises from the persistent infection of the cervical tissue by HPV, with HPV 16 being the most common type responsible for 50% of cervical cancer cases. There are other HPV oncogenic types, including HPV 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Normally, HPV infections clear within eight to 24 months of exposure, but if the infection persists, dysplasia may develop. If left untreated, dysplasia can progress to cervical cancer over several years. The slow progression allows for routine screening with a Pap smear and HPV testing, depending on the patient’s age and medical history. Various risk factors increase the likelihood of developing cervical dysplasia, including smoking, having multiple sex partners, human immunodeficiency virus (HIV) infection, early sexual activity, early childbirth, immunosuppressant drug usage (e.g., post-organ transplant), maternal exposure to DES (diethylstilbestrol), having three or more full-term pregnancies, and having a family history of cervical cancer. Cervical dysplasia exists in three forms, classified based on the extent of abnormal cell growth in the cervix:
1. CIN I – mild dysplasia (only the lower one-third of cells in the upper layer of the cervix are abnormal)
2. CIN II – moderate dysplasia (up to two-thirds of the layer contains abnormal cells)
3. CIN III – severe dysplasia to carcinoma in situ (precancerous cells are in the entire top layer of the cervix)
Treatment of cervical dysplasia depends on the degree of abnormality. Mild dysplasia may resolve spontaneously, and close monitoring with repeat Pap smears every three to six months is often sufficient. For moderate to severe dysplasia that does not resolve on its own, surgical removal of the abnormal tissue may be necessary to prevent the development of cervical cancer. There are several surgical procedures available, many of which can be performed on an outpatient basis, including cryo-cauterization or cryosurgery (using extreme cold to freeze or destroy abnormal cervical tissue), laser therapy (destroying abnormal tissue with a beam of light), loop electrosurgical excision procedure (LEEP, removing abnormal tissue with an electric current carried by a thin wire loop), and surgery (cone biopsy or cervical conization, involving the removal of a small cone-shaped sample of abnormal tissue from the cervix).

Thelansis’s “Cervical Dysplasia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cervical Dysplasia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Cervical Dysplasia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Cervical Dysplasia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Cervical Dysplasia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033